Ethyl Acetate

Ethyl Acetate

SCHEMBL130336

C1CCOC1.CCOC(C)=O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.64
LMNA P02545 3/20 0.64
HSD17B10 Q99714 1/20 0.64
TSHR P16473 3/20 0.48
POLB P06746 1/20 0.46
RECQL P46063 1/20 0.44
RAB9A P51151 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 3/20 0.38
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL3776197 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL15194119 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL16332300 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL6544884 1.00 ALDH1A1 (0.64) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL3909115 0.98 ALDH1A1 (0.61) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL1057423 0.98 ALDH1A1 (0.61) ALDH1A1LMNAHSD17B10TSHRPOLB
Cyclohexane SCHEMBL11112885 0.98 ALDH1A1 (0.61) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL3423313 0.98 ALDH1A1 (0.61) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL1873691 0.98 ALDH1A1 (0.61) ALDH1A1LMNAHSD17B10TSHRPOLB
Ethyl Acetate SCHEMBL28106135 0.98 ALDH1A1 (0.61) ALDH1A1LMNAHSD17B10TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118894777-A Caffeic acid crystal form and preparation method thereof 德州德药制药有限公司 2024-11-05 CN claimed
CN-117352658-A Double-ion battery in-situ electropolymerization positive electrode, battery and preparation method and application thereof 深圳先进技术研究院 2024-01-05 CN claimed
CN-115197075-A Preparation method of efavirenz key intermediate 盐城迪赛诺制药有限公司 2022-10-18 CN claimed
CN-112851623-B Method for preparing epsilon-caprolactone, 6-hydroxycaproic acid and ester thereof by using tetrahydrofurfuryl acetic acid and ester thereof 中国科学院兰州化学物理研究所 2022-04-08 CN claimed
CN-113968791-A Preparation method of efavirenz key intermediate 盐城迪赛诺制药有限公司 2022-01-25 CN claimed
CN-112851623-A Method for preparing epsilon-caprolactone, 6-hydroxycaproic acid and ester thereof by using tetrahydrofurfuryl acetic acid and ester thereof 中国科学院兰州化学物理研究所 2021-05-28 CN claimed
CN-106938980-A The preparation method of the carboxylic acid of one kind N of 5 benzyl 5 miscellaneous spiral shell [2.4] heptane 1 无锡捷化医药科技有限公司 2017-07-11 CN claimed
CN-105646634-A Preparation method of impurities of obeticholic acid 中国药科大学 2016-06-08 CN claimed
US-8680334-B2 Process for the preparation of iosimenol MALLINCKRODT LLC (US) 2014-03-25 US claimed
US-20130261338-A1 Process for the Preparation of Iosimenol MALLINCKRODT LLC (US) 2013-10-03 US claimed
CN-103265678-A Preparation method of xylitol aroma type polyurethane STATE GRID CORP CHINA 2013-08-28 CN claimed
EP-2240432-B1 PROCESS FOR THE PREPARATION OF IOSIMENOL MALLINCKRODT LLC (US) 2012-07-04 EP claimed
US-20100280270-A1 Process for the Prepartion of Iosimenol MNK 2011 LLC (F/K/A MALLINCKRODT INC.) 2010-11-04 US claimed
EP-2240432-A1 PROCESS FOR THE PREPARATION OF IOSIMENOL Mallinckrodt Inc. (US) 2010-10-20 EP claimed
CN-101817742-A Crystal form X of sofalcone, preparation method and use thereof TIANJIN INST PHARM RESEARCH 2010-09-01 CN claimed
WO-2009091758-A1 PROCESS FOR THE PREPARATION OF IOSIMENOL MALLINCKRODT INC. (US) 2009-07-23 WO claimed
EP-0284966-B1 Processes for the preparation of benzo (chalcogeno)[4,3,2-CD] indazoles WARNER-LAMBERT COMPANY (US) 1992-01-02 EP claimed
EP-0144386-B1 NOVEL PREPARATION OF NUCLEOSIDE PHOSPHORAMIDITE INTERMEDIATES BECKMAN INSTRUMENTS, INC. (US) 1989-09-06 EP claimed
US-4806654-A Processes for the preparation of benzo(chalcogeno)(4,3,2-cd)indazoles and intermediates thereof WARNER-LAMBERT COMPANY (US) 1989-02-21 US claimed
EP-0284966-A1 Processes for the preparation of benzo (chalcogeno)[4,3,2-CD] indazoles WARNER-LAMBERT COMPANY (US) 1988-10-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280270-A1 Process for the Prepartion of Iosimenol DHCR24, DRD4, NONO ALDH1A1 1647/4885LMNA 713/4885HSD17B10 3130/4885
US-20130261338-A1 Process for the Preparation of Iosimenol ITPR3, ITPR2, DHCR24 ALDH1A1 2309/4885LMNA 1642/4885HSD17B10 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.